Neurology | Links Medicus Content Curation & Alerts in Medicine

Perspective | Will unpredictable side effects dim the promise of new Alzheimer’s drugs?

8 Aug, 2023 | 13:30h | UTC

Will unpredictable side effects dim the promise of new Alzheimer’s drugs? – Science (a few articles per month are free)

RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns

Review | Treatment of pediatric convulsive status epilepticus

4 Aug, 2023 | 11:42h | UTC

Treatment of pediatric convulsive status epilepticus – Frontiers in Neurology

RCT | Recombinant human prourokinase demonstrates noninferiority to alteplase in acute ischemic stroke treatment

3 Aug, 2023 | 13:46h | UTC

Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial – JAMA Network Open

See also: Visual Abstract

Study | Frequent soccer heading linked to cognitive impairment risk in retired players

3 Aug, 2023 | 13:12h | UTC

Heading Frequency and Risk of Cognitive Impairment in Retired Male Professional Soccer Players – JAMA Network Open

Invited Commentary: Heading Frequency and Risk of Cognitive Impairment in Retired Male Professional Soccer Players – JAMA Network Open

Dementia risk in former professional footballers is related to player position and career length.

Study: Neurodegenerative Disease Mortality Increased Among Former Professional Soccer Players

Commentary on Twitter

In retired professional UK soccer players, repetitive heading was linked to an increased risk of cognitive impairment later in life by >2x (6-15/match) and >3x (>15x/match). https://t.co/lV2xNa1TTR

— JAMA Network Open (@JAMANetworkOpen) July 17, 2023

Review | Diagnosing delirium in perioperative and intensive care medicine

3 Aug, 2023 | 13:09h | UTC

Diagnosing delirium in perioperative and intensive care medicine – Current Opinion in Anesthesiology

RCT | Multiple sclerosis disease-modifying therapy continuation versus discontinuation in older individuals

2 Aug, 2023 | 14:00h | UTC

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial – The Lancet Neurology (link to abstract – $ for full-text)

Commentaries:

Study investigates risk when discontinuing therapy for MS patients over 55 – CU Anschutz Medical Campus

Discontinuing Multiple Sclerosis Therapies at Age 55 or Older – NEJM Journal Watch

RCT | Atogepant outperforms placebo in reducing migraines over 12 weeks

2 Aug, 2023 | 13:56h | UTC

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Cohort Study | Depression at any life stage linked to increased dementia incidence

2 Aug, 2023 | 13:49h | UTC

Association of Early-, Middle-, and Late-Life Depression With Incident Dementia in a Danish Cohort – JAMA Neurology (link to abstract – $ for full-text)

Commentary: Depression Over Adulthood May Increase Risk of Dementia – Psychiatric News Alert

Review | First-line immunosuppression in neuromuscular diseases

1 Aug, 2023 | 14:09h | UTC

First-line immunosuppression in neuromuscular diseases – Practical Neurology

Review | Multiple system atrophy

1 Aug, 2023 | 14:08h | UTC

Multiple system atrophy – Practical Neurology

Review | Clinical assessment of parietal lobe function

1 Aug, 2023 | 14:03h | UTC

Clinical assessment of parietal lobe function – Practical Neurology

Review | Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology

31 Jul, 2023 | 14:07h | UTC

Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology – Neurology

News Release: AAN issues guidance on new treatments for early Alzheimer’s disease – American Academy of Neurology

Phase 2 Trial | Oral orexin receptor 2 agonist shows promise in narcolepsy type 1, but raises hepatotoxic concerns

28 Jul, 2023 | 14:09h | UTC

Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1 – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

In a randomized trial involving patients with narcolepsy, an oral orexin receptor 2 agonist reduced sleepiness and cataplexy but had liver toxic effects. Read the full trial results: https://t.co/Go7lmQTu62

— NEJM (@NEJM) July 26, 2023

RCT – 2ry Analysis | Elevated intracranial bleeding risk with low-dose aspirin in older adults

27 Jul, 2023 | 13:09h | UTC

Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial – JAMA Network Open

See also: Visual Abstract

News Release: Low dose aspirin won’t help some older adults trying to avoid a stroke: study – Monash University

Commentary: Daily aspirin doesn’t prevent strokes in older, healthy people after all – The Conversation

Original Study: Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

Related Randomized Trials:

Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease

Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes

Related Meta-Analysis:

Meta-Analysis: Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events

Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups – BMC Medicine

Related Opinions:

Aspirin for Primary Prevention: Is This the End of the Road?

Evidence evolving on aspirin as prevention – ACP Internist

#347 USPSTF Update: Aspirin for Primary Prevention of CVD – The Curbsiders

Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness

26 Jul, 2023 | 13:28h | UTC

Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness – The Lancet Respiratory Medicine

RCT | Vitamin D supplementation shows no cognitive benefit in mild cognitive impairment intervention

25 Jul, 2023 | 14:00h | UTC

Effects of Exercise Alone or Combined With Cognitive Training and Vitamin D Supplementation to Improve Cognition in Adults With Mild Cognitive Impairment: A Randomized Clinical Trial – JAMA Network Open

Commentary: Exercise and Cognitive Training Slow Thinking Declines. Vitamin D? Not So Much – HealthDay

2ry analysis of a RCT | Vitamin D supplementation does not affect cognitive function in older adults

RCT: Oral Vitamin D supplementation (60.000 IU per month) did not reduce mortality in patients 60 years or older (unscreened individuals in Australia, many without insufficiency, average 30ng/mL). Exploratory analyses pointed towards an increased risk of death from cancer.

Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention

Association between vitamin D supplementation and mortality: systematic review and meta-analysis – The BMJ

USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases

Global, regional, and national burden of meningitis and its etiologies, 1990–2019

25 Jul, 2023 | 13:55h | UTC

Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 – The Lancet Neurology

Commentary on Twitter

Although largely preventable, meningitis still causes hundreds of thousands of deaths globally each year.

New @IHME_UW #GBDStudy in @TheLancetNeuro assesses incident cases and deaths due to acute infectious meningitis by aetiology and age from 1990–2019. https://t.co/S3KtMA7DMs pic.twitter.com/AYuSJHsNwK

— The Lancet (@TheLancet) July 20, 2023

Systematic Review | Existing research on post-stroke depression interventions lacks conclusive results

25 Jul, 2023 | 13:37h | UTC

Pharmacological, non‐invasive brain stimulation and psychological interventions, and their combination, for treating depression after stroke – Cochrane Library

Summary: Pharmacological, non-invasive brain stimulation and psychological interventions for treating depression after stroke – Cochrane Library

RCT | Hearing intervention fails to impact 3-year cognitive decline in older adults

20 Jul, 2023 | 11:09h | UTC

Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

#AAIC23 While hearing aids did not have an impact on cognitive decline over 3 years in a general population, treating hearing loss protected against cognitive decline in older adults at greater risk of dementia, finds a new trial: https://t.co/1UjGgDf5m5 pic.twitter.com/kuujeekCWW

— The Lancet (@TheLancet) July 18, 2023

Prospective Study | Intelligence likely remains intact after pediatric concussion

20 Jul, 2023 | 11:06h | UTC

IQ After Pediatric Concussion – Pediatrics (free for a limited period)

Commentaries:

IQ After Pediatric Concussion: Clinical Considerations – Pediatrics

No Evidence Seen for Differences in IQ After Pediatric Concussion – HealthDay

Concussions do not affect IQ in children, study finds – News Medical

RCT | Ischemic stroke patients benefit from Panax notoginseng saponins therapy

20 Jul, 2023 | 10:57h | UTC

Efficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China: A Randomized Clinical Trial – JAMA Network Open

See also: Visual Abstract

Commentary: Do Panax notoginseng saponins (Xuesaitong soft capsules) improve function in patients with ischemic stroke? – News Medical

Review | Painful diabetic peripheral neuropathy

20 Jul, 2023 | 10:53h | UTC

Painful Diabetic Peripheral Neuropathy: Practical Guidance and Challenges for Clinical Management – Diabetes, Metabolic Syndrome and Obesity

RCT | Solanezumab fails to slow cognitive decline in preclinical Alzheimer’s disease

19 Jul, 2023 | 14:26h | UTC

Trial of Solanezumab in Preclinical Alzheimer’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)

RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns

Commentary on Twitter

Original Article: Trial of Solanezumab in Preclinical Alzheimer’s Disease (A4 trial) https://t.co/lCXsVoiP8i #AAIC23 pic.twitter.com/e8DplR27yd

— NEJM (@NEJM) July 18, 2023